Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) Income from Continuing Operations (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Income from Continuing Operations for 7 consecutive years, with 78221000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 33.6% to 78221000.0 in Q4 2025 year-over-year; TTM through Nov 2025 was 264457000.0, a 36.62% decrease, with the full-year FY2025 number at 264457000.0, down 36.62% from a year prior.
  • Income from Continuing Operations was 78221000.0 for Q4 2025 at Nurix Therapeutics, up from 86421000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 24275000.0 in Q1 2021 to a low of 86421000.0 in Q3 2025.
  • A 5-year average of 44975250.0 and a median of 42998500.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: crashed 102.75% in 2021, then surged 46.53% in 2023.
  • Nurix Therapeutics' Income from Continuing Operations stood at 37689000.0 in 2021, then fell by 23.95% to 46717000.0 in 2022, then increased by 10.19% to 41956000.0 in 2023, then crashed by 39.55% to 58549000.0 in 2024, then plummeted by 33.6% to 78221000.0 in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Income from Continuing Operations are 78221000.0 (Q4 2025), 86421000.0 (Q3 2025), and 43464000.0 (Q2 2025).